Company intelligence / Profile preview

CD Biopharma

Suzhou, Jiangsu Province, Chinacdbiopharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company’s lead candidate, CD‑001, has received FDA IND clearance and entered Phase I clinical trials. Preclinical studies showed efficacy in mouse tumor models and good tolerance in non-human primates. An armored PD1Ab21-CD19 CAR-T therapy has shown complete remission in the first three patients of an investigator-led trial at a top Beijing hospital with well-managed safety. Initial clinical data from the ongoing trial are expected soon.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Bispecific fusion proteins (BsFP)Armored CAR-T cell therapyMonoclonal antibodiesAntibody-cytokine fusion proteins
Industry: Biotech

Drug pipeline

3 assets

PD-1Ab21-CAR-T

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on CD Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD Biopharma.

Explore the full profile